Science
Rami Manochakian: Lurbinectedin Faces FDA Withdrawal After Negative Phase 3 Trial in SCLC
Rami Manochakian/X

Rami Manochakian: Lurbinectedin Faces FDA Withdrawal After Negative Phase 3 Trial in SCLC

Rami Manochakian, Thoracic Medical Oncologist at Mayo Clinic Florida, shared on X:

“Hot off the press. Jazz Pharmaceuticals plans to ask U.S. FDA to withdraw:

Lurbinectedin (Zepzelca) approval in 2nd line Tx of Small Cell Lung Cancer (SCLC). This is based on Negative Lagoon phase 3 trial that showed NO OS benefit.”

Rami Manochakian

Other articles about SCLC on OncoDaily.

cancer Lung cancer Lurbinectedin OncoDaily Oncology Rami Manochakian SCLC small cell lung cancer Zepzelca